Role of Climate Change on Oriental Spruce (Picea orientalis L.): Modeling and Mapping

Global climate change is a process with dramatic consequences for ecosystems, and changes that may occur in the potential distribution of plant communities especially draw attention. This study aimed to reveal the potential distribution modeling and mapping of the Oriental spruce (Picea orientalis L.), distributed in a limited area, using current and future (year 2100) climate scenarios in Turkey. The maximum entropy method for potential distribution and Chelsa V2.1 technical specification IPSL-CM6A-LR scenarios (SSP126-SSP370-SSP585) were preferred to reveal the effect of climate change. Results for the current were in the “excellent” category with training and test data AUC 0.981 and 0.977, respectively. The variables contributing to the model were the precipitation amount of the driest month, mean diurnal air temperature range, annual precipitation amount, and mean annual air temperature. Variables contributing to the current model were analysed using the SSP126, SSP370, and SSP585 scenarios of the year 2100. It was assessed that the potential distribution for 2100 decreases according to SSP126, was fragmented according to SSP370, and decreased according to the SSP585 scenario. As a result, the authors determined that the high potential distribution is reduced 61% when the current mapping of Oriental spruce is compared with the SSP585 mapping

Cognistat Nöropsikoloji Testinin standartize edilmesi ve Alzheimer demanslı olgularda uygulanması

Bu tezin, veri tabanı üzerinden yayınlanma izni bulunmamaktadır. Yayınlanma izni olmayan tezlerin basılı kopyalarına Üniversite kütüphaneniz aracılığıyla (TÜBESS üzerinden) erişebilirsiniz.ÖZET Bu çalışmada nöropsikoloji alanında bir tarama testi olan Cognistat nöropsikoloji testinin standardizasyonu ve Alzheimer hastalarında etkinliğinin kontrolü planlanmıştır.Testin standartizasyonu 50 - 59 yaş, 60 - 69 yaş ve 70 yaş ve üstü olmak üzere 3 ayrı grup için yapılmıştır. Toplam 93 olgu standardizasyon için çalışmaya alınmıştır. Alzheimer hastalığı bulunan 86 olgu çalışmaya alınmıştır. Her iki gruba Cognistat nöropsikoloji testi ve MMSE, Alzheimer hastalarına ek olarak global bozulma ölçeği uygulanmıştır. Normal örneklemin her 3 ayrı yaş grubu için ortalama değerler ve standart sapmaları hesaplanmıştır. Testin kendi içerisinde tutarlı bir test olduğunu gösterebilmek için ise alt testler arasında korelasyonlar hesaplanmıştır. Yine normal örneklem MMSE ile karşılaştırılmıştır. Hasta örneklemin de alt testleri için ortalama ve standart sapma değerleri hesaplanmıştır. Yine alt testler arasındaki korelasyonlar hesaplanmıştır. Hasta örneklem grubu MMSE ve Global Bozulma Skoru ile karşılaştırılmıştır. Normal örneklemden elde edilen veriler ile MMSE karşılaştırıldığında istatistiksel olarak 2 test arasında anlamlı bir uyum saptanmıştır. Aynı sonuçlar hasta örneklem için de elde edilmiştir. Hasta ve normal örneklem MMSE değerleri karşılaştığında anlamlı derecede farklı puanlar saptanmıştır. Aynı farklılık Cognistat nöropsikoloji testinin normal örneklem ve hasta örneklemi için de geçerdir. Normal örneklemden elde edilen değerler ile 3 ayrı yaş grubu için Cognistat nöropsikoloji testi standardize edilmiştir. Bu çalışma Cognistat nöropsikoloji testinin demansta tarama testi olarak güvenle kullanılabileceğini, ancak kognitif alanlarda saptanan bozuklukları demans olarak yorumlayabilmek için mutlaka hastanın günlük yaşam aktivitelerinde bir aksama olup olmadığının saptanması, bunun içinde iyi bir öykü veya günlük yaşam aktivitesini değerlendiren bir test bataryası ile desteklenmesi gerektiğini göstermiştir. «

Post-ischemic Holmes' tremor of the lower extremities

WOS: 000272037300017PubMed ID: 19662325Holmes' tremor, which is known to occur as a result of different lesions centered in the brain stem, cerebellum and thalamus, is a tremor of low frequency, mostly below 4.5 Hz (Deuschl and Bergman in Mov Disord 17(suppl 3):S41-S48, 2002). We present a patient who developed a tremor, mostly involving her lower extremities, secondary to an ischemic infarct affecting the cerebellum, thalamus and midbrain. Attempts at medical treatment with levodopa, quetiapine and levetirecetam all failed. However, pribedil, a dopaminergic receptor-stimulating agent, successfully improved the tremor. Our case is interesting as published reports generally focus on tremors limited to the upper extremities except for one reported case of Holmes' tremor involving the lower extremities more severely (Walker et al. in Mov Disord 22(2):272-274, 2007). It also demonstrates that dopaminergic receptor stimulating agents should be tested before considering invasive therapies

The Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraine

WOS: 000365428100008Introduction: Resistant chronic migraine (RCM) causes a considerable decline in the quality of life and work efficiency of the patients and ultimately might even decrease their socioeconomic level because of severe and permanent headaches. In addition, migraine attacks force patients to rush to the emergency rooms, which leads to overcrowding and exhaustion of medical resources. In this study, the effect of onabotulinum toxin A (OBoNT-A) treatment was assessed in terms of efficiency and the quality of life retrospectively at patients with RCM. Method: 15 patients with RCM who were given 155 IU OBoNT-A treatment twice in 12 weeks have been studied retrospectively in terms of change of headache frequency, severity, and the health related quality of life scores (physical function, physical restriction, pain, general health, vitality, social function, emotion and mental health categories) for 24 weeks. Response to treatment is identified as >= 30% decrease in headache frequency while the change in the quality of life was determined with short form-36 before and after treatment. Findings: Average headache frequency was 26.3 day/month before treatment. After 24 weeks, 93% of the patients were responsive to the treatment. After OBoNT-A treatment average headache frequency decreased to 16,6 day/month in 12 weeks and to 17,8 day/month in 24 weeks (p<0.001). Average health related quality of life scores before treatment were under 50%, while all the health related quality of life scores improved after treatment(p<0.001). At the end of 24 weeks, headache severity significantly decreased (p<0.001). Conclusion: OBoNT-A is an effective treatment in patients with RCM and it must be considered a first line treatment for RCM patients considering the cost-effectiveness researches

Gerstmann Syndrome; A Frequent Pathology Presenting With A Rare Symptomatology

WOS: 000312600000020We report a case of glioblastoma multiforme (GBM) of the left parietal lobe presenting with Gerstmann Syndrome (GS). A 54-year-old woman presented dyscalculia. The computed tomography depicted a cystic mass in the left parietal lobe, thus she was referred to our department. Her detailed neurological examination revealed left-right disorientation, finger agnosia and agraphia with dyscalculia. Pathological examination of the tumor revealed GBM. This most common primary malignancy of the central nerve system rarely presents with GS. Detailed neurological examination may locate the pathology of the brain prior to the radiological examinations and is still precious despite the rapid progression of the radiological technologies

Efficacy of Low-dose Pramipexole Augmentation in the Treatment of Refractory Psychotic Depression Complicated with Tardive Dyskinesia: A Case Report

WOS: 000297959300008Efficacy of low-dose pramipexole augmentation in the treatment of refractory psychotic depression complicated with tardive dyskinesia: a case report Tardive dyskinesia (TD) is a severe complication of antipsychotic treatment. Pramipexole can be effective in the treatment of TD due to its D3 dopamine receptor agonist effect. Studies conducted in bipolar depression and treatment-resistant depression (TRD), support the antidepressant effect of pramipexole. Here we present the case of a 55 year-old female. For the treatment of depression, she received antidepressants, anxiolytics and antipsychotics for 2.5 years. When severe bruxism, fidgeting, and serious functional impairment emerged, she was re-hospitalized and diagnosed with TRD and TD. Several combinations of antidepressants, anxiolytic, and antipsychotics were administered. The depression improved partially, but hypochondriac preoccupations and dyskinesia persisted. At the sixth month, pramipexole 0.125 mg/day was added to sertraline 200 mg/day, amitriptyline 60 mg/day, clonazepam 2 mg/day, and biperiden 4 mg/day. The depression and dyskinesia improved and she was discharged. TRD and TD improved within the first 4 weeks of pramipexole administration and no relapse was observed. Pramipexole is a promising agent in the treatment of TRD and TD